{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:04:43Z","timestamp":1785859483665,"version":"3.56.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Systemic anaplastic large cell lymphoma with cutaneous involvement can mimic other malignancies and delay treatment. A 71-year-old Filipino woman had 18 months of minimally symptomatic plaques and nodules; a right-hip nodule enlarged to an 8 \u00d7 8 \u00d7 5-cm mass. She underwent radical wide excision of the right-hip mass and scalp nodules; only the hip specimen was submitted for histopathology and was read as a malignant spindle cell tumor favoring alveolar rhabdomyosarcoma, with rapid recurrence at the hip and scalp surgical sites. On referral, she had plaques and nodules, crusted scalp lesions, and lymphadenopathies. Repeat biopsies from scalp and recurrent hip lesions showed a dermal\u2013subcutaneous infiltrate of large atypical lymphocytes with mitoses and periadnexal\/intravascular involvement; immunohistochemistry was CD30\/CD3\/CD45 positive and ALK\/EMA negative, consistent with ALK-negative systemic ALCL with cutaneous involvement. Staging revealed stage IV disease with extranodal metastases and elevated LDH. After a dose of ifosfamide\/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK\/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.<\/jats:p>","DOI":"10.1097\/dad.0000000000003301","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:00:35Z","timestamp":1776283235000},"page":"e75-e79","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ALK-Negative Systemic Anaplastic Large Cell Lymphoma With Multifocal Cutaneous Involvement Responding to Brentuximab Vedotin"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9441-7463","authenticated-orcid":false,"given":"Matthew S.","family":"Abad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flordeliz","family":"Abad-Casintahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Ernest A.","family":"Casintahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"1","key":"R1-20260722","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pathol.2019.09.007","article-title":"ALCL by any other name: the many facets of anaplastic large cell lymphoma","volume":"52","author":"Irshaid","year":"2020","journal-title":"Pathology"},{"key":"R2-20260722","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/PAP.0000000000000047","article-title":"Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous","volume":"22","author":"Xing","year":"2015","journal-title":"Adv Anat Pathol"},{"key":"R3-20260722","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2015.12.053","article-title":"Cutaneous anaplastic large-cell lymphoma: a comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site","volume":"74","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260722","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.897","article-title":"Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?","volume":"27","author":"Fornari","year":"2009","journal-title":"Hematological Oncol"},{"key":"R5-20260722","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0037-1963(03)00138-0","article-title":"Systemic and primary cutaneous anaplastic large cell lymphomas","volume":"40","author":"Kadin","year":"2003","journal-title":"Semin Hematol"},{"key":"R6-20260722","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ad.2010.09.015","article-title":"Skin involvement as the presenting feature of primary systemic anaplastic lymphoma kinase-negative CD30+ anaplastic lymphoma","volume":"102","author":"Messeguer","year":"2011","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"R7-20260722","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2012.06.004","article-title":"Anaplastic large cell lymphoma, ALK-negative","volume":"85","author":"Ferreri","year":"2013","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"R8-20260722","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma, ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"R9-20260722","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0970-9371.86363","article-title":"Anaplastic large cell lymphoma: the evolution continues","volume":"28","author":"Das","year":"2011","journal-title":"J Cytol"},{"key":"R10-20260722","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/2278-330X.214575","article-title":"Systemic and primary cutaneous anaplastic large cell lymphoma: clinical features, morphological spectrum, and immunohistochemical profile","volume":"6","author":"Kwatra","year":"2017","journal-title":"South Asian J Cancer"},{"key":"R11-20260722","doi-asserted-by":"crossref","first-page":"Article 35","DOI":"10.3892\/mco.2024.2733","article-title":"Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma","volume":"20","author":"Gleason","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"R12-20260722","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"R13-20260722","first-page":"e1581","article-title":"Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed\/refractory peripheral T-cell lymphoma","volume":"5","author":"Gentille","year":"2022","journal-title":"Cancer Rep"},{"key":"R14-20260722","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ejh.13568","article-title":"Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma","volume":"106","author":"Van de Wyngaert","year":"2021","journal-title":"Eur J Haematol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:11:44Z","timestamp":1785856304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003301","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}